scholarly journals Can acetylcysteine ameliorate cisplatin‐induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double‐blind, placebo‐controlled trial involving patients with head and neck cancer

2019 ◽  
Vol 8 (5) ◽  
pp. 2020-2030 ◽  
Author(s):  
Marília B. Visacri ◽  
Júlia C. F. Quintanilha ◽  
Vanessa M. Sousa ◽  
Laís S. Amaral ◽  
Rosiane Ambrósio ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Antitumor Efficacy ◽  
Double Blind ◽  
Double Blind Placebo ◽  
And Oxidative Stress

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

The Lancet ◽  
2003 ◽  
Vol 362 (9392) ◽  
pp. 1255-1260 ◽  
Author(s):  
Michael Henke ◽  
Roland Laszig ◽  
Christian Rübe ◽  
Ulrich Schäfer ◽  
Klaus-Dieter Haase ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals A Randomized Double-Blind Placebo-Controlled Trial of Fruit and Vegetable Concentrates on Intermediate Biomarkers in Head and Neck Cancer

2017 ◽  
Vol 17 (1) ◽  
pp. 115-123
Author(s):  
Mridul Datta ◽  
Edward G. Shaw ◽  
Glenn J. Lesser ◽  
L. Douglas Case ◽  
Mara Z. Vitolins ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Second Primary ◽  
Double Blind ◽  
Ki 67 ◽  
Primary Tumors ◽  
Double Blind Placebo ◽  
Increased Risk

Background. Head and neck cancer (HNC) patients are at an increased risk for developing second primary tumors (SPTs). Diets rich in fruits and vegetables (FVs) may lower HNC risk. FV concentrates may offer a potential alternative to increasing FV intake. Methods. We conducted a randomized, double-blind, placebo-controlled trial to evaluate whether Juice PLUS+ (JP; a commercial product with multiple FV concentrates) has an effect on p27 and Ki-67, biomarkers associated with the risk of SPTs. During 2004-2008, we randomized 134 HNC patients to 12 weeks of JP (n = 72) or placebo (n = 62). Oral cavity mucosal biopsies and whole blood were obtained at baseline and after 12 weeks. All participants were given the opportunity to receive JP for 5 years following the end of the intervention period, and they were followed yearly for the development of SPTs. Results. After 12 weeks, patients on JP had significantly higher serum α-carotene ( P = .009), β-carotene ( P < .0001), and lutein ( P = .003) but did not differ significantly in p27 ( P = .23) or Ki-67 ( P = .95). JP use following the initial 12-week trial was not significantly associated with SPT prevention. Conclusions. Despite increased serum micronutrient levels, our results do not suggest a clinical benefit of JP in HNC patients. Future studies should focus on longer intervention periods and/or modified supplement formulations with demonstrated chemopreventive properties.

scholarly journals Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer

Oral Oncology ◽  
2014 ◽  
Vol 50 (11) ◽  
pp. 1098-1103 ◽  
Author(s):  
Rajesh V. Lalla ◽  
Linda E. Choquette ◽  
Kathleen F. Curley ◽  
Robert J. Dowsett ◽  
Richard S. Feinn ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document